A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore,Begoña Mellado,Satish Shah,Ralph J. Hauke,Dan Costin,Thomas Morris,Rana Anjum,Zsolt Szíjgyártó,Remy B Verheijen,Marie Cullberg

A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

2021

Neal D. Shore
Begoña Mellado
Satish Shah
Ralph J. Hauke
Dan Costin
Thomas Morris
Rana Anjum
Zsolt Szíjgyártó
Remy B Verheijen
Marie Cullberg

85Background: Androgen receptor (AR) targeting therapies prolong survival of patients with metastatic castration-resistant prostate cancer (mCRPC); however, in many cases, resistance develops, resu...

Keywords:

Abiraterone acetate
Androgen receptor
Oncology
Prostate cancer
castration resistant
phase i study
in patient
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations